Dry Eye Disease Market Research Report 2030 | Dry Eye Disease Market

What is Dry Eye Disease?

Dry eye disease is a common condition that happens when your tears aren't able to provide adequate lubrication for your eyes. Tears are often inadequate and unstable for several reasons. For instance, dry eyes may occur if you do not produce enough tears or if you produce poor-quality tears.

DelveInsight's new launch on "Dry Eye Disease Market report 2030” delivers an in-depth understanding of the Dry Eye Disease, historical and forecasted epidemiology also as the Dry Eye Disease market trends within the 7MM.

Dry Eye Disease Sign and Symptoms

Dry eyes feel uncomfortable. If you've got dry eyes, your eyes may sting or burn. You'll experience dry eyes in certain situations, like in an air-conditioned room, while riding a motorcycle or after watching a display screen for a couple of hours.

Dry Eye Disease Signs and symptoms, which usually may affect both eyes, may include:

1. A burning or scratchy sensation in your eyes
2. Sensitivity to light
3. Eye redness
4. Difficulty wearing contact lenses
5. Watery eyes
6. Eye fatigue

Request for sample pages of the report: https://www.delveinsight.com/sample-request/dry-eye-disease-market-insights

Dry Eye Disease Treatment Therapies and Options

For most people with occasional or mild dry eye symptoms, it's enough to regularly use over-the-counter eye drops. If your symptoms are persistent and more serious, you've got other options.

Prescription medications used to treat dry eyes include:

●     Drugs to reduce eyelid inflammation

●     Eye-drops to control cornea inflammation

●     Tear-stimulating drugs

Other procedures that may be used to treat dry eyes include:

●     Closing your tear ducts to reduce tear loss

●     Using special contact lenses

●     Unblocking oil glands

●     Using light therapy and eyelid massage

The Dry Eye Disease market report 2030 provides Dry Eye Disease treatment algorithms and therapies in the 7mm.

Dry Eye Disease Epidemiology Insights

One study found that 17 percent of 2,127 patients visiting a hospital in Japan were diagnosed with dry eyes, while 14.6 percent in a group of 2,520 older individuals reported symptoms of dry eyes. Dry eye syndrome can occur at any age, and in otherwise healthy people.

●        According to a study, the general Dry Eye Disease prevalence was 5.28%, wherein the prevalence among females and males was about 7.78% and 2.96%, respectively,

●        The overall Dry Eye Disease prevalence between 2003 and 2015, estimated among approximately 9.7 million MHS beneficiaries, was 5.28%.

●        Overall prevalence was higher among females (7.78%) than male beneficiaries (2.96%) and increased with age.

This section of the DelveInsight Dry Eye Disease report also includes information on the diagnosed patient pool, trends, and assumptions used.

For each of the seven major countries, the Dry Eye Disease epidemiology section provides information on historical and present Dry Eye Disease patient pools, as well as predicted trends.

Got queries? Click here to read more about Dry Eye Disease Market Trends

Dry Eye Disease Market Insights

The treatments of Dry Eye Disease are varied. The goals of treatment are to alleviate the symptoms of dry eye, improve the patient’s comfort, return the ocular surface and tear film to the traditional state, and, whenever possible, prevent corneal damage.

Key Insights:

●        Many companies are involved within the ongoing research, which is aimed toward achieving more detailed knowledge of inflammatory pathways and targeting various sorts of inflammatory mediators in dry eye patients.

●        Recent advances within the understanding of tear film physiology and pathology have allowed the formulation of a spread of tear substitutes capable of addressing specific deficiencies of tear components.

●        Key players, like Oyster Point Pharma, Kala Pharmaceuticals, Ocugen, Topivert, Aurinia Pharmaceuticals, Novaliq, and lots of others are involved in developing therapies for Dry Eye Disease, they're expected to vary the market scenario of Dry disease within the upcoming years.

By assessing the impact of current medicines on the market, unmet needs, drivers and barriers, and demand for better technologies, the Dry Eye Disease market outlook report helps to establish a complete understanding of historic, present, and future Dry Eye Disease market trends.

According to DelveInsight, the Dry Eye Disease market in 7MM is expected to change in the study period 2017-2030.

Dry Eye Disease Emerging Therapy Assessment

1. OC-01/OC-02 : Oyster Point Pharma
2. OCU 310 : Ocugen
3. HMB9036 : HanAll Biopharma
4. MC2-03 : mc2 therapeutics
5. ECF843 : Novartis
6. Voclosporin ophthalmic solution : Aurinia Pharmaceuticals
7. KPI-121 : Kala Pharmaceuticals

OC-01/OC-02: Oyster Point Pharma

Oyster Point Pharma is developing a lead product candidate, OC-01 which is a highly selective nAChR agonist and is being developed for the treatment of signs and symptoms of Dry Eye Disease.

MC2-03: mc2 therapeutics

Using PAD Technology, Mc2 therapeutics is developing MC2-03 which is a new cyclosporine eye drop that's designed to uniquely improve the delivery of cyclosporine into the eyes using a vehicle/eye drop that's highly tolerable.

ECF843: Novartis

ECF843 is a recombinant human lubricin protein, developed by Lubris LLC, in-licensed by Novartis. It's a new therapeutic approach and potential first-in-class treatment in dry-eye, which may be a small phase II clinical trial study that showed the potential to produce instant relief of symptoms.

The emerging therapy assessment segment of the Dry Eye Disease report encloses a detailed analysis of Dry Eye Disease marketed drugs and late-stage pipeline drugs.

Visit our repository of reports @ DelveInsight Report Store

About DelveInsight       

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.